NeuroSense
Therapeutics
New Hope on The Horizon
About
NeuroSense
NeuroSense was born with the intent to answer the huge unmet need of patients with amyotrophic lateral sclerosis (ALS) with the understanding that this devastating disease must be addressed from a new perspective.
NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people living with ALS, as well as other neurodegenerative diseases. We are focused on creating combined therapeutic strategies, targeting the multiple pertinent mechanisms in these complex diseases.
About
NeuroSense
NeuroSense was born with the intent to answer the huge unmet need of patients with amyotrophic lateral sclerosis (ALS) with the understanding that this devastating disease must be addressed from a new perspective.
NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people living with ALS, as well as other neurodegenerative diseases. We are focused on creating combined therapeutic strategies, targeting the multiple pertinent mechanisms in these complex diseases.
“Never believe that a few caring people can’t change the world.
For, indeed, that’s all who ever have.”
— Margaret Mead
Combined Therapy
Neurodegenerative diseases are complex with many underlying pathologies. Our goal is to create combined therapies targeting the multiple pathways affected by these conditions. Therefore, we research the diseases’ core mechanisms and then develop combined therapies to target them in an optimal way and synergistic manner.
Expedited Development
For ALS, NeuroSense is developing PrimeC, a unique formulation of a fixed-dose combination drug comprising ciprofloxacin and celecoxib. The development of PrimeC is well underway; it has been successfully tested in a phase 2a clinical trial in patients with ALS. Additionally, NeuroSense has received a patent for the drug, as well as a Seal of Excellence for our development program from Horizon 2020, a research and innovation funding program operated by the European Union. PrimeC has been granted orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Recent Updates
Join Our Newsletter
